PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
Synapse
⌘+K
Synapse
May 29, 2026Journal of Clinical Oncology

GT101 autologous TIL therapy in patients with recurrent and metastatic cervical cancer: A phase 1 study.

View Full Paper
Ask AI
Bookmark
Share

Authors

PWPin WangHQHaifeng QinYWYongsheng Wang

Discussion

Loading...

Member takes

Overview

Randomized trial evaluates GT101 therapy's safety and efficacy in patients with cervical cancer, suggesting potential for further development.

Key Points

  • To assess the safety and preliminary efficacy of GT101 in patients with recurrent or metastatic cervical cancer.
  • Phase I, open-label, single-arm multicenter trial (NCT05430373)
  • Eleven patients received lymphodepletion followed by GT101 infusion and high-dose IL-2.
  • Endpoints included safety assessments and objective response rates according to RECIST v1.1.
  • Overall response rate (ORR) was 45.5% (5/11) with a disease control rate (DCR) of 90.9% (10/11).
  • Median duration of response (DoR) was 6.4 months, and median progression-free survival (PFS) was 4.83 months.
  • No treatment-related serious adverse events (SAEs) were reported, with most adverse events being Grade 1-2.

Cite This Study

Wang et al. (2026) studied this question.

synapsesocial.com/papers/6a192f1bfab5b468c44186f6https://doi.org/10.1200/jco.2026.44.16_suppl.5532
View Full Paper
Ask AI
Bookmark
Share